Salud financiera de hoja de balance de TRxADE HEALTH

Salud financiera controles de criterios 2/6

TRxADE HEALTH tiene un patrimonio de los accionistas total de $-1.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $3.7M y $5.0M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$745.56k
Patrimonio	-US$1.29m
Total pasivo	US$5.04m
Activos totales	US$3.74m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: 4E40 tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: 4E40 tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: 4E40 está libre de deudas.

Reducción de la deuda: 4E40 tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 4E40 tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si 4E40 tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de TRxADE HEALTH

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

Recent updates

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera